Literature DB >> 2202385

Determinants of gait in the elderly parkinsonian on maintenance levodopa/carbidopa therapy.

S G Bowes1, P K Clark, A L Leeman, C J O'Neill, C Weller, P W Nicholson, A A Deshmukh, S M Dobbs, R J Dobbs.   

Abstract

1. We have used gait analysis to investigate the efficacy of maintenance therapy with a levodopa/carbidopa combination in patients with idiopathic Parkinsonism, who do not have overt fluctuations in control in relation to administration of medication. 2. Fourteen patients (aged 64 to 88 years) receiving maintenance therapy with levodopa and carbidopa (Sinemet Plus) entered a placebo-controlled, randomised cross-over study of the effect of omission of a morning dose of active treatment on distance/time parameters of gait. Measurements made 2, 4 and 6 h after the morning treatment were standardised by taking the pre-treatment measurement on that day as baseline. 3. The mean increase in stride length (7%) and decrease in double support time (20%) on active treatment were small but statistically significant (P less than 0.0001, in each case), there being no significant placebo effect on either gait parameter (P = 0.69 and 0.08 respectively). Neither active nor placebo treatments had any significant (P greater than 0.45 in each case) effect on the lying, standing or postural fall in mean arterial pressure, measurements being made in the same temporal relation to the treatments as was gait. 4. In a generalised linear model, after allowing for the effect (P less than 0.0001) of intrinsic variability in pre-treatment speed as well as for structure of the study, nature of treatment had an effect on stride length over the whole walk, significant at P = 0.002. 5. Pre-treatment postural fall in mean arterial pressure was nearly as significant (P = 0.003) as the nature of treatment in the context of such a model: the greater the fall, the greater the increment in stride length seen following active or placebo treatment. This was probably explained by an acquired tolerance to the fall as the day progressed. 6. The major determinant (P less than 0.0001) of the change in double support time over the whole walk, after allowing for the structure of the study, appeared to be the post treatment mean arterial standing blood pressure. The lower the pressure, the shorter the double support time, and hence, the greater the tendency to a hurried gait. 7. Nature of treatment, when added into the models described in summary points 5 and 6, had no significant effect (P greater than 0.25, in each case).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2202385      PMCID: PMC1368270          DOI: 10.1111/j.1365-2125.1990.tb03738.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Parkinson's disease.

Authors:  N P Quinn; F A Husain
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-09

2.  An assessment of various methods of treatment of idiopathic orthostatic hypotension.

Authors:  R Bannister; L Ardill; P Fentem
Journal:  Q J Med       Date:  1969-10

3.  Orthostatic hypotension in Parkinson's disease.

Authors:  M Gross; R Bannister; R Godwin-Austen
Journal:  Lancet       Date:  1972-01-22       Impact factor: 79.321

4.  Treatment of Parkinson's disease with levodopa and Ro 4-4602.

Authors:  A Barbeau; L Gillo-Joffroy; H Mars
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

5.  Autonomic deficits in Parkinson's syndrome.

Authors:  O Appenzeller; J E Goss
Journal:  Arch Neurol       Date:  1971-01

6.  Cardiovascular reflexes in Parkinsonism.

Authors:  J L Reid; D B Calne; C F George; C Pallis; S D Vakil
Journal:  Clin Sci       Date:  1971-07       Impact factor: 6.124

7.  Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa.

Authors:  A L Leeman; C J O'Neill; P W Nicholson; A A Deshmukh; M J Denham; J P Royston; R J Dobbs; S M Dobbs
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

8.  Determination of urinary and plasma dihydroxyphenylalanine by coupled-column high-performance liquid chromatography with C8 and C18 stationary phases.

Authors:  C R Benedict; M Risk
Journal:  J Chromatogr       Date:  1984-12-28

9.  Parkinsonism in the elderly.

Authors:  M Hildick-Smith
Journal:  Curr Med Res Opin       Date:  1982       Impact factor: 2.580

10.  Bringing gait analysis out of the laboratory and into the clinic.

Authors:  L Klenerman; R J Dobbs; C Weller; A L Leeman; P W Nicholson
Journal:  Age Ageing       Date:  1988-11       Impact factor: 10.668

View more
  14 in total

1.  Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson's disease.

Authors:  H Stolze; J P Kuhtz-Buschbeck; H Drücke; K Jöhnk; M Illert; G Deuschl
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-03       Impact factor: 10.154

2.  Effects of levodopa on forward and backward gait patterns in persons with Parkinson's disease.

Authors:  M S Bryant; D H Rintala; J G Hou; E C Lai; E J Protas
Journal:  NeuroRehabilitation       Date:  2011       Impact factor: 2.138

3.  Gait quantitation in Parkinson's disease--locomotor disability and correlation to clinical rating scales.

Authors:  P Vieregge; H Stolze; C Klein; I Heberlein
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  Objective outcome criteria in trials of anti-parkinsonian therapy in the elderly: sensitivity, specificity and reliability of measures of brady- and hypo-kinesia.

Authors:  S G Bowes; P K Clark; A Charlett; C J O'Neill; A L Leeman; C Weller; P W Nicholson; A A Deshmukh; S M Dobbs; R J Dobbs
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 5.  Pharmacological treatment in Parkinson's disease: Effects on gait.

Authors:  Katrijn Smulders; Marian L Dale; Patricia Carlson-Kuhta; John G Nutt; Fay B Horak
Journal:  Parkinsonism Relat Disord       Date:  2016-07-17       Impact factor: 4.891

6.  Effect of captopril on functional, physiological and biochemical outcome criteria in aged heart failure patients.

Authors:  C J O'Neill; A Charlett; R J Dobbs; A A Deshmukh; S G Bowes; C Weller; P W Nicholson; J S Milledge; S M Dobbs
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

7.  Striatal dopaminergic denervation and gait in healthy adults.

Authors:  R Cham; S A Studenski; S Perera; N I Bohnen
Journal:  Exp Brain Res       Date:  2007-11-01       Impact factor: 1.972

8.  Advances in Therapeutic Options for Gait and Balance in Parkinson's Disease.

Authors:  Nicolaas I Bohnen; Roger L Albin; Martijn L T M Müller; Kelvin Chou
Journal:  US Neurol       Date:  2011-11-01

9.  Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.

Authors:  S G Bowes; R J Dobbs; M Henley; A Charlett; C J O'Neill; P W Nicholson; A G Purkiss; C Weller; S M Dobbs
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  Dopaminergic and non-dopaminergic gait components assessed by instrumented timed up and go test in Parkinson's disease.

Authors:  Valeria Dibilio; Alessandra Nicoletti; Giovanni Mostile; Simona Toscano; Antonina Luca; Loredana Raciti; Giorgia Sciacca; Rosario Vasta; Calogero Edoardo Cicero; Donatella Contrafatto; Mario Zappia
Journal:  J Neural Transm (Vienna)       Date:  2017-10-10       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.